BlueRock Therapeutics

Headquarters: Cambridge, Massachusetts, USA Founded: 2016 Parent Company: Bayer AG (acquired 2019) Pipeline Focus: Cell therapy for Parkinson's disease and other neurological disorders

Overview

Headquarters: Cambridge, Massachusetts, USA Founded: 2016 Parent Company: Bayer AG (acquired 2019) Pipeline Focus: Cell therapy for Parkinson's disease and other neurological disorders

Overview

BlueRock Therapeutics is a clinical-stage biotechnology company pioneering cell-based regenerative therapies for neurological diseases. The company's lead candidate, bemdaneprocel (BRII-001), is an investigational dopamine neuron replacement therapy for Parkinson's disease that has demonstrated promising results in Phase I clinical trials["@tabar2025"].

Founded in 2016 as a venture between Bayer AG and Versant Ventures, BlueRock leverages its proprietary pluripotent stem cell platform to generate specialized cell products for tissue repair and regeneration. The company's mission focuses on developing curative cell therapies that address the underlying neurodegeneration in Parkinson's disease rather than merely managing symptoms["@bluerock"].

Parkinson's Disease Pipeline

Bemdaneprocel (BRII-001 / exPDite-2)

Mechanism: Dopamine neuron replacement therapy using human embryonic stem cell (hESC)-derived dopaminergic progenitor cells

Stage: Phase III (exPDite-2)

Status: Enrolling

Bemdaneprocel (also known as exPDite-2 in the Phase III trial) is an investigational cryopreserved, off-the-shelf dopaminergic neuron progenitor cell product derived from human embryonic stem cells. The therapy aims to replace the dopamine-producing [neurons](/entities/neurons) lost in Parkinson's disease by transplanting progenitor cells into the patient's brain, where they mature into functional dopamine neurons[@tabar2025][@kirkeby2024].

Clinical Development:

• Phase I (NCT04802733): Completed in 12 patients with advanced Parkinson's disease
• Phase III (exPDite-2, NCT05887418): Registrational trial enrolling ~102 patients, expected completion 2027-2028
• Two sequential cohorts in Phase I: low-dose (0.9 million cells) and high-dose (2.7 million cells)
• Bilateral putamenal grafting with one year of immunosuppression
• 24-month follow-up data published in Nature (2025)[@tabar2025]

• Primary safety and tolerability objectives achieved at one year
• No adverse events related to the cell product reported
• At 18-24 months, putaminal 18Fluoro-DOPA positron emission tomography (PET) uptake increased, indicating graft survival
• Improvement in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III OFF scores by an average of 23 points in the high-dose cohort (21.9-point improvement)
• No graft-induced dyskinesias observed[@tabar2025][@parmar2024]

Technology Platform

Pluripotent Stem Cell Platform

BlueRock's proprietary platform enables:

The platform builds on foundational research in human embryonic stem cell differentiation toward midbrain dopaminergic neurons, building on protocols developed by Studer and colleagues[@kriks2011][@studer2022].

Dopamine Neuron Replacement

The company's approach addresses the root cause of Parkinson's disease by:

• Replacing lost dopamine-producing neurons in the substantia nigra
• Restoring natural dopamine synthesis and release
• Providing potential disease modification rather than symptomatic relief
• Offering durable effects from a single treatment[@grealish2023][@barker2023]

Business and Financials

Funding History

• 2016: Founded with $225M Series A funding (largest biotech Series A at the time)
• 2019: Acquired by Bayer AG for approximately $600M upfront plus up to $400M in milestones

Strategic Partnership with Bayer

Following the acquisition, BlueRock operates as a wholly-owned subsidiary of Bayer AG, maintaining its research operations in Cambridge, Massachusetts. The partnership provides significant resources for clinical development and leverages Bayer's global manufacturing and commercialization capabilities[@bayer].

Market Position

BlueRock represents Bayer's flagship cell therapy asset in the neuroscience space. The company positions itself at the forefront of regenerative medicine, with potential applications beyond Parkinson's disease to other neurological conditions characterized by neuronal loss.

Leadership and Scientific Advisors

BlueRock's leadership combines biotech entrepreneurship with deep expertise in stem cell biology and neurosurgery:

• Scientific Founders: The company originated from research by Dr. Lorenz Studer and Dr. Viviane Tabar at Memorial Sloan Kettering Cancer Center
• Clinical Leadership: Phase I trial led by Dr. Viviane Tabar with contributions from Dr. Mark T. Kitt
• Executive Team: Experienced biotech executives with track records in cell therapy development

Clinical Evidence

Tabar et al. Nature 2025

The landmark Phase I trial results were published in Nature, demonstrating the safety and preliminary efficacy of bemdaneprocel[@tabar2025]:

> "These data demonstrate safety and support future definitive clinical studies."

The trial represents a significant milestone in cell therapy for Parkinson's disease, establishing the foundation for future clinical development of dopamine neuron replacement approaches.

Ongoing Development

BlueRock continues to advance bemdaneprocel through clinical development, with plans for expanded Phase II trials with larger patient cohorts, longer-term follow-up to assess durability of benefits, and optimization of delivery and immunosuppression protocols.

Research and Development Focus

BlueRock's R&D strategy emphasizes cell replacement therapies that replace lost neurons, disease modification targeting underlying disease mechanisms, platform expansion applying cell therapy platform to additional neurological conditions, and manufacturing innovation improving scalable cell production methods[@tomishima2024].

Competitive Landscape

BlueRock competes with other cell therapy approaches for Parkinson's disease, including International Stem Cell Corporation developing neural stem cell therapies, Aspen Neuroscience working on autologous neuron replacement, Kyowa Kirin supporting research in dopamine neuron transplantation, and Summit Biomedical developing small molecule approaches. BlueRock's differentiation lies in its use of hESC-derived progenitors with demonstrated graft survival and functional integration in human patients.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• -

Cross-References

• [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
• [Cell Therapy](/therapeutics/cell-therapy-neurodegeneration)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [PD Pipeline Companies](/companies/pd-pipeline-companies)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Bayer](/companies/bayer)

References